TCDA - Tricida, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.90
+0.52 (+1.56%)
At close: 4:00PM EDT

33.90 0.00 (0.00%)
After hours: 4:27PM EDT

Stock chart is not supported by your current browser
Previous Close33.38
Open33.48
Bid34.03 x 1000
Ask44.98 x 800
Day's Range33.33 - 34.96
52 Week Range19.43 - 42.80
Volume152,031
Avg. Volume250,276
Market Cap1.666B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.74
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.50
Trade prices are not sourced from all markets
  • Does Tricida's (NASDAQ:TCDA) Share Price Gain of 35% Match Its Business Performance?
    Simply Wall St.25 days ago

    Does Tricida's (NASDAQ:TCDA) Share Price Gain of 35% Match Its Business Performance?

    Passive investing in index funds can generate returns that roughly match the overall market. But one can do better...

  • Should Tricida (NASDAQ:TCDA) Be Disappointed With Their 35% Profit?
    Simply Wall St.25 days ago

    Should Tricida (NASDAQ:TCDA) Be Disappointed With Their 35% Profit?

    Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...

  • Here’s What Hedge Funds Think About Tricida, Inc. (TCDA)
    Insider Monkey26 days ago

    Here’s What Hedge Funds Think About Tricida, Inc. (TCDA)

    Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying before the Q4 market crash that the stock market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the first […]

  • Business Wire27 days ago

    Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet

    Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced that The Lancet published online detailed results from its long-term, Phase 3, multicenter, parallel, randomized, blinded, placebo-controlled trial, TRCA-301E, in 196 patients with CKD and metabolic acidosis. “This new data highlights the value of treating metabolic acidosis in patients with CKD,” said Donald E. Wesson, M.D., M.B.A., Professor of Medicine at Texas A&M Health Science Center College of Medicine in Dallas, TX, lead investigator of the study and primary author of The Lancet paper.

  • Zacks.com featured highlights include: Stifel, Napco, Tricida and Under Armour
    Zackslast month

    Zacks.com featured highlights include: Stifel, Napco, Tricida and Under Armour

    Zacks.com featured highlights include: Stifel, Napco, Tricida and Under Armour

  • 4 Stocks Set to Pop on New Analyst Coverage
    Zackslast month

    4 Stocks Set to Pop on New Analyst Coverage

    Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.

  • Business Wire2 months ago

    Tricida to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

    Tricida, Inc. (TCDA) today announced that it will present at the Goldman Sachs 40th Annual Health Care Conference on Wednesday, June 12, 2019 at 10:00 am PT. Gerrit Klaerner, Tricida’s Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the company’s key initiatives. Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).

  • Tricida, Inc. (TCDA) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Tricida, Inc. (TCDA) Q1 2019 Earnings Call Transcript

    TCDA earnings call for the period ending March 31, 2019.

  • Business Wire2 months ago

    Tricida Announces First Quarter 2019 Financial Results

    Webcast Today at 4:30 pm Eastern Time

  • Did Hedge Funds Drop The Ball On Tricida, Inc. (TCDA) ?
    Insider Monkey3 months ago

    Did Hedge Funds Drop The Ball On Tricida, Inc. (TCDA) ?

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]

  • Business Wire3 months ago

    Tricida to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, May 8, 2019

    Tricida, Inc. (TCDA) today announced that it will report its first quarter 2019 financial results after the close of market on Wednesday, May 8, 2019. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its financial results and business progress.

  • What Kind Of Shareholder Owns Most Tricida, Inc. (NASDAQ:TCDA) Stock?
    Simply Wall St.3 months ago

    What Kind Of Shareholder Owns Most Tricida, Inc. (NASDAQ:TCDA) Stock?

    A look at the shareholders of Tricida, Inc. (NASDAQ:TCDA) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller compa...

  • Here's What Drove Tricida 67% Higher in March
    Motley Fool3 months ago

    Here's What Drove Tricida 67% Higher in March

    It looks like the company found an easy solution to a big problem.

  • Business Wire3 months ago

    Tricida Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Tricida, Inc. today announced the closing of its previously announced public offering of 6,440,000 shares of its common stock at a public offering price of $36.00 per share, which includes the exercise in full by the underwriters of their option to purchase 840,000 additional shares of common stock for total gross proceeds of approximately $231.8 million, before deducting underwriting discounts and ...

  • The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy
    Zacks4 months ago

    The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

    The Zacks Analyst Blog Highlights: Alpine, Actinium, Molecular Templates, Tricida and Otonomy

  • Business Wire4 months ago

    Tricida Announces Pricing of Public Offering of Common Stock

    Tricida, Inc. today announced the pricing of its public offering of 5,600,000 shares of its common stock at a public offering price of $36.00 per share for total gross proceeds of $201.6 million, before deducting underwriting discounts and commissions and other offering expenses payable by Tricida.

  • Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy
    Zacks4 months ago

    Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

    Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

  • Why MAG Silver, comScore, and Tricida Slumped Today
    Motley Fool4 months ago

    Why MAG Silver, comScore, and Tricida Slumped Today

    Even on a great day on Wall Street, these companies couldn't share in the good news.

  • Business Wire4 months ago

    Tricida Announces Proposed Public Offering of Common Stock

    Tricida, Inc. (TCDA) today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock. All of the shares in the offering will be sold by Tricida. In addition, Tricida expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of its common stock in the offering.

  • Will Tricida Continue to Surge Higher?
    Zacks4 months ago

    Will Tricida Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Tricida.

  • TheStreet.com4 months ago

    Tricida Surges on Positive Results of Chronic Kidney Disease Treatment

    saw a surge in its stock after it produced positive results from its chronic kidney disease treatment. The stock soared about 57%, or $13.73, to close at $37.80 Thursday after results showed the company's drug TRC101, more commonly known as Veverimer, met its primary and secondary endpoints, the company said in a press release. The treatment is designed to reduce metabolic acidosis in patients affected by chronic kidney disease.

  • Here's Why Tricida's Soaring Today
    Motley Fool4 months ago

    Here's Why Tricida's Soaring Today

    Clinical trial results were a bit better than expected.

  • Tricida Inc (TCDA) Q4 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Tricida Inc (TCDA) Q4 2018 Earnings Conference Call Transcript

    TCDA earnings call for the period ending December 31, 2018.

  • Business Wire4 months ago

    Tricida Announces Positive Results From Long-Term Clinical Trial of TRC101 in Patients With CKD and Metabolic Acidosis

    Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today results from its blinded, randomized, placebo-controlled, multicenter clinical trial, TRCA-301E, in 196 CKD patients with metabolic acidosis. TRC101 represents a first-in-class drug candidate for the treatment of metabolic acidosis, a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.

  • Business Wire4 months ago

    Tricida Announces $200 Million Debt Facility With Hercules Capital

    Tricida, Inc. (TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate TRC101 (veverimer), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it has entered into an amendment to its existing debt facility with Hercules Capital, Inc. (HTGC), a leader in customizing debt financing for companies in the life sciences and technology-related markets. Tricida originally entered into a $100 million debt facility with Hercules Capital in February 2018.